摘要
范可尼贫血是一种DNA修复缺陷综合征,其主要特点是癌症易感性和骨髓衰竭。慢病毒载体介导的基因治疗临床试验最被提出,试图在恢复这些患者的造血功能。然而,因为对于DNA修复缺陷综合征如范可尼贫血,到目前为止没有插入癌变的研究,我们通过LAM-PCR和454焦磷酸测序进行了Fanca-造血干细胞(HSC)的基因矫正,然后进行了后的慢病毒插入位点的全基因组筛选。我们的研究首次证明:带有用于临床应用的慢病毒载体的Fanca-造血干细胞的转导有效地纠正了范可尼贫血再生细胞的表型,无任何毒性迹象。超过6500的插入位点在原发性和继发性受体的鉴定显示了多克隆的重建模式,以及被矫正的Fanca-造血干细胞克隆体的连续周转,而没有对于特定的常见整合位点的选择的证据。综合我们的数据显示,对于DNA修复缺陷综合征,慢病毒载体介导的基因治疗有效地纠正了被影响的造血干细胞的表型并推动了体内克隆周转的康健模式。这些研究将对DNA修复基因综合征特别是范可尼贫血患者的新基因治疗试验的发展造成特别的影响。
关键词: 慢病毒载体,范可尼贫血,基因治疗,整合点。
Current Gene Therapy
Title:Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs
Volume: 15 Issue: 6
Author(s): F. Javier Molina-Estevez, Ali Nowrouzi, MLuz Lozano, Anne Galy, Sabine Charrier and Christof von Kalle, Guillermo Guenechea, Juan A. Bueren and Manfred Schmidt
Affiliation:
关键词: 慢病毒载体,范可尼贫血,基因治疗,整合点。
摘要: Fanconi anemia is a DNA repair-deficiency syndrome mainly characterized by cancer predisposition and bone marrow failure. Trying to restore the hematopoietic function in these patients, lentiviral vector-mediated gene therapy trials have recently been proposed. However, because no insertional oncogenesis studies have been conducted so far in DNA repair-deficiency syndromes such as Fanconi anemia, we have carried out a genome-wide screening of lentiviral insertion sites after the gene correction of Fanca-/- hematopoietic stem cells (HSCs), using LAM-PCR and 454-pyrosequencing. Our studies first demonstrated that transduction of Fanca-/- HSCs with a lentiviral vector designed for clinical application efficiently corrects the phenotype of Fanconi anemia repopulating cells without any sign of toxicity. The identification of more than 6,500 insertion sites in primary and secondary recipients showed a polyclonal pattern of reconstitution, as well as a continuous turnover of corrected Fanca-/- HSC clones, without evidences of selection towards specific common integration sites. Taken together our data show, for the first time in a DNA repair-deficiency syndrome, that lentiviral vector-mediated gene therapy efficiently corrects the phenotype of affected HSCs and promotes a healthy pattern of clonal turnover in vivo. These studies will have a particular impact in the development of new gene therapy trials in patients affected by DNA repair syndromes, particularly in Fanconi anemia.
Export Options
About this article
Cite this article as:
F. Javier Molina-Estevez, Ali Nowrouzi, MLuz Lozano, Anne Galy, Sabine Charrier and Christof von Kalle, Guillermo Guenechea, Juan A. Bueren and Manfred Schmidt , Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs, Current Gene Therapy 2015; 15 (6) . https://dx.doi.org/10.2174/1566523215666150929110903
DOI https://dx.doi.org/10.2174/1566523215666150929110903 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reviewing Antiviral Research against Viruses Causing Human Diseases -
a Structure-Guided Approach
Current Molecular Pharmacology MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA FK506 Binding Proteins as Targets in Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?
Current Drug Targets Influence of Toll-Like-Receptor Ligands on the Dendritic Cell - T Cell Interactions: Therapeutic Options for Allergic Diseases? Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Regulation of Iron Absorption in Hemoglobinopathies
Current Molecular Medicine The Therapeutic Potential of Toll-Like Receptor 7 Stimulation in Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Molecules of Parasites as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging Hypoxia and Fetal Heart Development
Current Molecular Medicine Targeted Drug Delivery Systems for Lung Macrophages
Current Drug Targets The Role of Psychiatrist in Organ Transplantation: From Gate-keeper to Patient's Advocate
Current Psychiatry Reviews The Emerging Diabetes Online Community
Current Diabetes Reviews Molecular Basis of Inflammation and Insulin Resistance in Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Sulfonyl Group-Containing Compounds in the Design of Potential Drugs for the Treatment of Diabetes and Its Complications
Current Medicinal Chemistry Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Understanding Genetic Factors in Idiopathic Scoliosis, a Complex Disease of Childhood
Current Genomics Molecular Mechanisms Involved in the Aging of the T-cell Immune Response
Current Genomics